Jazz takes groundbreaking epilepsy drug into kids in Phase III trial
Jazz Pharma is breaking new ground with its cannabidiol epilepsy treatment Epidiolex, taking the drug into a Phase III study in children and adolescents.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
U.S. to boost monkeypox vaccine supply, adding 1.8 million doses
/in TherapeuticsThe United States will boost its supply of monkeypox vaccine by making an additional 1.8 million doses of Bavarian Nordic’s Jynneos vaccine available for ordering starting Aug. 22, the White House said on Thursday.
Paxlovid rebound: RWE analysis and alternative therapies in development
/in Issue ArchivesResearchers at Case Western University looked at the real-world experiences of 13,644 patients who were treated with Paxlovid or Lagevrio (molnupiravir) during the first half of 2022. The study was intended to determine the prevalence of three types of rebound outcomes with these two therapies, each of which has emergency use authorizations as treatments for COVID-19. In that study (currently in preprint on medRxiv, co-author Pamela Davis, M.D. and colleagues found that the 7-day and 30-day rebound rates associated with Paxlovid treatments, respectively, were 3.53% and 5.4% for COVID-19 reinfection; 2.31% and 5.87% for COVID-19 symptoms; and 0.44% and 0.77% for hospitalizations.
Genentech, Roche sink potential $600M into advanced prostate cancer asset
/in R&D, TherapeuticsGenentech has signed an exclusive worldwide license agreement with Chinese pharmaceutical firm Jemincare to allow the latter to develop and commercialize JMKX002992, an androgen receptor degrader being developed for prostate cancer.
Bavarian Nordic seeks help as monkeypox vaccine supply line crumbles
/in Business, TherapeuticsCases of monkeypox are growing at an alarming rate and Bavarian Nordic, the company that owns Jynneos, one of the two approved vaccines, may no longer be able to keep up, according to a report by Bloomberg.
Germany’s constitutional court upholds measles vaccine mandate for children
/in TherapeuticsThe German constitutional court upheld the country’s measles vaccine mandate for children on Thursday, ruling against a challenge brought by parents.
Valneva: U.S. Dept. of Defense ends Ixiaro vaccine supply deal
/in TherapeuticsThe U.S. Department of Defense (DoD) has ended an encephalitis vaccine supply contract with Valneva, said the French drugmaker, adding that a slowdown in global travel activity, mainly affecting Asia, had led to lower demand.
Bluebird’s $2.8M gene therapy becomes most expensive drug after U.S. approval
/in FDA/Regulatory, TherapeuticsThe U.S. Food and Drug Administration on Wednesday approved bluebird bio’s gene therapy for patients with a rare disorder requiring regular blood transfusions, and the drugmaker priced it at a record $2.8 million.
U.S. CDC plans to focus on public health response after pandemic failings
/in FDA/Regulatory, TherapeuticsThe U.S. Centers for Disease Control and Prevention said it will prioritize its public health response in a revamp of its structure after months of criticism over its handling of the COVID-19 and monkeypox pandemics.
Inizio strengthens leadership team with two key appointments
/in Marketing & AdvertisingInizio, a strategic partner for health and life sciences with a full suite of advisory, medical, marketing, communications, and patient and stakeholder engagement services, appointed two key strategic hires.